Teva announces the launch of a generic version of ALOXI® in the U.S.
Teva announced the launch of a generic version of ALOXI® (palonosetron HCI) injection, 0.25 mg/5 mL, in the U.S. Palonosetron hydrochloride injection—in a class of medications called 5-HT3 receptor antagonists—used in adults to prevent nausea and vomiting that may occur as a result of chemotherapy. March 23, 2018